Wytwarzanie produktów leczniczych jest dla nas nie tylko kwestia wykonania pewnego procesu technologicznego, ale misją związaną z człowiekiem opartą na wysokim standardzie jakości, bezpieczeństwa i skuteczności leków.
Mamy aktywną i kluczową rolę w podnoszeniu standardów życia codziennego. Sprawiamy, że społeczeństwo jest lepiej poinformowane, zdrowsze, szczęśliwsze i bezpieczniejsze
Sofia, Bulgaria, December 14 2023 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on December 13, 2023 the Company bought 184 000 (one hundred and eighty-four thousand) own shares representing 0.107% of the share capital of the Company, at a total value of BGN 1 122 400 on the Bulgarian Stock Exchange, the average price per share was BGN 6,10.
Sofia, Bulgaria, December 13 2023 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on December 12, 2023 the Company bought 150 000 (one hundred and fifty thousand) own shares representing 0.087% of the share capital of the Company, at a total value of BGN 915,000 on the Bulgarian Stock Exchange, the average price per share was BGN 6,10.
Sofia, Bulgaria, December 12, 2023 - Pursuant to the requirements of Art. 100t of the Law on Public Offering of Securities, "Sopharma" AD (SFA: BSE AD, SPH: Warsaw Stock Exchange) announces that on the basis of Art. 187b of the Commercial Law and Art. 111, para. 5 and para.